title: Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitis.
abstract: The intestinal microbiome is a reservoir of microbial antigens and activated immune cells. The aims of this review were to describe the role of the intestinal microbiome in generating innate and adaptive immune responses, indicate how these responses contribute to the development of systemic immune-mediated diseases, and encourage investigations that improve the understanding and management of autoimmune hepatitis. Alterations in the composition of the intestinal microflora (dysbiosis) can disrupt intestinal and systemic immune tolerances for commensal bacteria. Toll-like receptors within the intestine can recognize microbe-associated molecular patterns and shape subsets of T helper lymphocytes that may cross-react with host antigens (molecular mimicry). Activated gut-derived lymphocytes can migrate to lymph nodes, and gut-derived microbial antigens can translocate to extra-intestinal sites. Inflammasomes can form within hepatocytes and hepatic stellate cells, and they can drive the pro-inflammatory, immune-mediated, and fibrotic responses. Diet, designer probiotics, vitamin supplements, re-colonization methods, antibiotics, drugs that decrease intestinal permeability, and molecular interventions that block signaling pathways may emerge as adjunctive regimens that complement conventional immunosuppressive management. In conclusion, investigations of the intestinal microbiome are warranted in autoimmune hepatitis and promise to clarify pathogenic mechanisms and suggest alternative management strategies.
authors.affiliation: Albert J Czaja, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, United States.
authors.forename: Albert J
authors.initials: AJ
authors.lastname: Czaja
mesh_terms: D056704:Adaptive Immunity; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000942:Antigens, Bacterial / Q000276:immunology; D015551:Autoimmunity / Q000187:drug effects; D064806:Dysbiosis; D000069196:Gastrointestinal Microbiome / Q000187:drug effects / Q000276:immunology*; D019693:Hepatitis, Autoimmune / Q000276:immunology / Q000382:microbiology* / Q000628:therapy; D054884:Host-Pathogen Interactions; D006801:Humans; D007113:Immunity, Innate; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007422:Intestines / Q000187:drug effects / Q000276:immunology / Q000382:microbiology*; D008213:Lymphocyte Activation; D019936:Probiotics / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D000942:Antigens, Bacterial; D007166:Immunosuppressive Agents
keywords: Autoimmune hepatitis; Dysbiosis; Inflammasomes; Intestinal microbiome; Toll-like receptors